Eyenovia, INC 10-K annual reports

Eyenovia, Inc. files an amendment to its 2024 Annual Report on Form 10-K to include previously omitted information regarding directors, executive compensation, security ownership, related transactions, and principal accountant fees.

Eyenovia is exploring strategic alternatives and cutting costs after a negative clinical trial result, raising concerns about its ability to continue as a going concern.

Eyenovia, Inc. has filed an amendment to its annual report on Form 10-K for the fiscal year ended December 31, 2023, to include previously omitted information regarding directors, executive compensation, and other corporate governance matters.

Eyenovia's annual 10-K filing details their commercialization efforts for Mydcombi and clobetasol propionate, along with strategic changes in their pipeline and manufacturing.